Network pharmacology analysis and molecular docking technology were used to explore the potential mechanism of action of diosmin against renal fibrosis, and the key therapeutic targets of diosmin were identified as CASP3, MMP9, ANXA5, and HSP90AA1. Here, MMP9 is linked to renal fibrosis.